Emerging therapeutic directions for inotropic therapy in heart failure

Area of Science:

• Cardiology
• Pharmacology
• Biomedical Engineering

Background:

• Heart failure (HF) is a significant global health issue, with current treatments primarily focusing on neurohormonal modulation.
• Guideline-directed medical therapy (GDMT) for HF with reduced ejection fraction (HFrEF) slows progression but doesn't restore contractile function.
• Conventional inotropes improve contractility but are associated with adverse outcomes in HFrEF patients.

Purpose of the Study:

• To review the pathophysiologic mechanisms underlying impaired cardiac contractility in HFrEF.
• To examine novel therapeutic strategies aimed at enhancing myocardial contractility.
• To discuss the potential of these emerging therapies in reshaping the treatment landscape for acute and chronic HF.

Main Methods:

• Literature review of pathophysiologic mechanisms of contractility deficits in HFrEF.
• Analysis of preclinical and clinical data for novel inotropic agents and small molecules.
• Evaluation of mechanisms of action for both traditional and emerging contractility-enhancing therapies.

Main Results:

• Identified novel therapeutic approaches that enhance cardiac contractility without the adverse effects of conventional inotropes.
• Discussed the therapeutic potential of emerging small molecules and other novel strategies.
• Highlighted a shift towards direct myocardial modulation from indirect neurohormonal modulation.

Conclusions:

• Novel therapeutic strategies offer a paradigm shift in HF treatment, moving towards direct myocardial modulation.
• These interventions hold promise for targeted, efficacious, and safer treatments for acute and chronic HF.
• Future research should focus on translating these novel contractility-enhancing therapies into clinical practice for HFrEF patients.